JPRN-jRCT2080225307已完成2 期
A phase 2, randomized, placebo-controlled, double-blind study of TAS-303 in female patients with stress urinary incontinence
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 186
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- Female
入选标准
- •Key Inclusion Criteria:
- •-Patient has symptoms of Stress Urinary Incontinence (SUI) for at least 12 weeks prior to study entry
- •-Urinary incontinence in the 1-hour pad weight test exceeds 2.0 g
- •-The average number of SUI episodes is 1 or more per day
- •- The average number of urge urinary incontinence (UUI) episodes is 0.43 or less per day
- •-The number of SUI episodes exceeds the number of other episodes
- •-The average number of urinary diurnal frequency is 10 or less per day and the average number of nocturia frequency is 2 or less per day
排除标准
- •Key Exclusion Criteria:
- •- Patient has been diagnosed with mixed urinary incontinence (MUI) that is predominantly UUI
- •- Patient has treated medication or therapy for SUI within 14 days before prior to study entry
- •- Patient is considered to have SUI that would not be expected to improve unless treated with surgical therapy
- •- Patient had a history of surgical treatment for urinary incontinence (Trans-obturator tape surgery, Tension-free vaginal tape surgery, etc.)
- •- Patient has stage II or more of Pelvic Organ Prolapse (POP), or had a history of POP repair surgery within 180 days before prior to study entry
- •- Patient has a serious illness or medical condition
研究者
相似试验
进行中（未招募）
2 期
A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysisHyperphosphatemiaJPRN-jRCT2031220587Mita Seiji150
未知
2 期
A phase 2, randomized, placebo-controlled, double-blind, crossover study of DS-8500a to evaluate the effects on pancreatic beta cell function in Japanese patients with type 2 diabetes mellitusType 2 Diabetes MellitusJPRN-jRCT2080223072DAIICHI SANKYO CO., LTD.20
进行中（未招募）
1 期
A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing complex cardiac surgery (CARDIAC)Prevention of organ dysfunction induced by inflammatory response after complex cardiac surgeryMedDRA version: 20.0Level: PTClassification code 10063101Term: Post procedural inflammationSystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 20.0Level: LLTClassification code 10062357Term: SIRSSystem Organ Class: 100000004867EUCTR2015-003036-12-DEInflaRx GmbH
进行中（未招募）
1 期
A Clinical Study to evaluate Ladarixin as an additional therapy to improve glycemic control in overweight insulin resistance patients with type 1 diabetes.EUCTR2022-000743-68-ITDOMPé FARMACEUTICI S.P.A.86
进行中（未招募）
1 期
A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate safety, pharmacokinetics, pharmacodynamics and to estimate efficacy of the new humanized monoclonal i.v. administered antibody CaCP29EUCTR2013-001037-40-DEInflaRx GmbH72